Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Oct 19;6:35383. doi: 10.1038/srep35383

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016, The Author(s)

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

(A) SUM159, MDA, SCP2, and MCF7 cells are treated with 100 nM of the CDK4 inhibitor palbociclib for 48 hours. Total cell number was calculated and quantified (upper panel). Total cell lysates were then subjected to immunoblotting using p-RB and β-tubulin antibodies (bottom panel). (B) Gene expression of CD44, CD24, or CDK4 was analyzed in different breast cancer subtypes, including triple-negative (TN), HER2 positive (HER2+), and hormone receptor positive (HR) in 51 breast cancer cell lines, using GOBO gene set analysis. (C,D) SUM159, MDA, and MCF7 cells were treated with or without palbociclib for 2 days, labeled with an anti-CD44 conjugated to APC antibody and with an anti-CD24 conjugated to PE antibody and analyzed by flow cytometry. Percentages of the different CD44^+/−/CD24^+/− subpopulations were graphed and quantified using flowJ.